These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18322050)

  • 1. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease.
    Raggi P; Kleerekoper M
    Clin J Am Soc Nephrol; 2008 May; 3(3):836-43. PubMed ID: 18322050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vitamin D, cardiovascular disease and mortality in patients with kidney disease].
    Hansen D; Brandi L; Rasmussen K
    Ugeskr Laeger; 2009 Dec; 171(50):3684-9. PubMed ID: 20003863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
    Yano S
    Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
    Goodman WG
    Semin Dial; 2004; 17(3):209-16. PubMed ID: 15144547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
    Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
    Bailie GR; Massry SG;
    Pharmacotherapy; 2005 Dec; 25(12):1687-707. PubMed ID: 16305288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Santagostino G; Gallieni M; Brancaccio D
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of vitamin D in vascular calcification in chronic kidney disease.
    Wolisi GO; Moe SM
    Semin Dial; 2005; 18(4):307-14. PubMed ID: 16076354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of vitamin D deficiency in chronic kidney disease.
    Gal-Moscovici A; Sprague SM
    J Bone Miner Res; 2007 Dec; 22 Suppl 2():V91-4. PubMed ID: 18290730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic kidney disease/bone and mineral metabolism: the imperfect storm.
    Williams ME
    Semin Nephrol; 2009 Mar; 29(2):97-104. PubMed ID: 19371800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.
    Gesek FA; Desmond JS
    Nephrol Nurs J; 2008; 35(2 Suppl):5S-22S; quiz 23S. PubMed ID: 18505229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified.
    Ix JH; Quarles LD; Chertow GM
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):337-9. PubMed ID: 16932455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal models--what they can tell us about vascular calcification in CKD.
    Massy ZA; Slama M; Tribouilloy C; Drüeke TB
    Semin Dial; 2007; 20(2):110-2. PubMed ID: 17374083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vitamin D deficiency in kidney failure. Risk factor for cardiovascular disease].
    Ohman K; Larsson T; Spaak J
    Lakartidningen; 2010 Nov 17-23; 107(46):2884-7. PubMed ID: 21197784
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D; Tatematsu M
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.